Combination therapy: Appropriate for everyone?

Journal of Asthma

Volumn 40, Issue 4, 2003, Pages 431-444

  Bensch, George ^a,c   Prenner, Bruce M ^b  

^a Allerg Immunol/Asthma M G Inc   (United States)

^b Allergy Associates Medical Group Inc   (United States)

^c NONE   (United States)

Author keywords

Additive therapy; Asthma; Combination therapy; Cromolyn; Fluticasone; Inhaled corticosteroids; Leukotriene receptor antagonists; Long acting beta agonists; Montelukast; Nedocromil; Salmeterol; Zafirlukast

Indexed keywords

BAMBUTEROL; BECLOMETASONE DIPROPIONATE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; FLUTICASONE PROPIONATE PLUS SALMETEROL; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIPOXYGENASE INHIBITOR; LONG ACTING DRUG; MONTELUKAST; NEDOCROMIL; NONSTEROID ANTIINFLAMMATORY AGENT; SALMETEROL; THEOPHYLLINE; ZAFIRLUKAST; ZILEUTON;

ADD ON THERAPY; ANTICHOLINERGIC EFFECT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; BRONCHODILATING ACTIVITY; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DOSE RESPONSE; DRUG APPROVAL; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; HEALTH CARE ORGANIZATION; HUMAN; IMMUNOMODULATION; LOW DRUG DOSE; MEDICAL DECISION MAKING; MEDICAL PRACTICE; PATIENT COUNSELING; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; QUALITY OF LIFE; SIDE EFFECT; THEOPHYLLINE BLOOD LEVEL;

ANTI-ASTHMATIC AGENTS; ASTHMA; CLINICAL TRIALS; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; DRUG TOLERANCE; HUMANS; PRACTICE GUIDELINES; SELF ADMINISTRATION; TREATMENT OUTCOME;

EID: 0038502139     PISSN: 02770903     EISSN: None     Source Type: Journal    
DOI: 10.1081/JAS-120018783     Document Type: Article

References (78)

1. Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, National Institutes of Health, 1997.
2. Nelson HS. Advair: combination treatment with fluticasone propionate/salmeterol in the treatment of asthma. J Allergy Clin Immunol 2001; 107(2):398-416.
3. Advair Diskus [monograph]. Research Park, NC: GlaxoSmithKline, 2000.
4. Gross G, Thompson PJ, Chervinsky P, Vanden Burgt J. Hydrofluoroalkane-134a beclomethasone dipropionate, 400 μg, is as effective as chlorofluorocarbon beclomethasone dipropionate, 800 μg, for the treatment of moderate asthma. Chest 1999; 115(2): 343-351.
5. Corren J, Nelson H, Greos L, Bensch G, Goldstein M, Wu J, Wang S, Newman K. Effective control of asthma with hydrofluoroalkane flunisolide delivered as an extra fine aerosol in asthma patients. Ann Allergy Asthma Immunol 2001; 87:405-411.
6. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med 1999; 159(9):941-955.
7. Lipworth BJ, Jackson CM. Safety of inhaled and intranasal corticosteroids: lessons for the new millennium. Drug Saf 2000; 23(1):11-33.
8. Davies RJ, Stampone P, O'Connor BJ. Hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol provides equivalent asthma control to chlorofluorocarbon beclomethasone dipropionate at approximately half the total daily dose. Respir Med 1998; 92(suppl A):23-31.
9. Lal S, Dorow PD, Venho KK, Chatterjee SS. Nedocromil sodium is more effective than cromolyn sodium for the treatment of chronic reversible obstructive airway disease. Chest 1993; 104(2):438-447.
10. O'Hickey SP, Rees PJ. High-dose nedocromil sodium as an addition to inhaled corticosteroids in the treatment of asthma. Respir Med 1994; 88(7):499-502.
11. Svendsen UG, Jorgensen H. Inhaled nedocromil sodium as additional treatment to high dose inhaled corticosteroids in the management of bronchial asthma. Eur Respir J 1991; 4(8):992-999.
12. Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med 2000; 343(15):1054-1063.
13. Ukena D, Harnest U, Sakalauskas R, Magyar P, Vetter N, Steffen H, Leichtl S, Rathgeb F, Keller A, Steinijans VW. Comparison of addition of theophylline to inhaled steroid with doubling of the dose of inhaled steroid in asthma. Eur Respir J 1997; 10(12):2754-2760.
14. Evans DJ, Taylor DA, Zetterstrom O, Chung KF, O'Connor BJ, Barnes PJ. A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. N Engl J Med 1997; 337(20):1412-1418.
15. Singulair [package insert]. Whitehouse Station, NJ: Merck & Co., Inc., 2001.
16. Virchow JC Jr, Prasse A, Naya I, Summerton L, Harris A, Zafirlucast Study group. Zafirlucast improves asthma control in patients receiving high-dose inhaled corticosteroids. Am J Respir Crit Care Med 2000; 162:578-585.
17. Laviolette M, Malmstrom K, Lu S, Chervinsky P, Pujet JC, Peszek I, Zhang J, Reiss TF. Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/beclomethasone additivity group. Am J Respir Crit Care Med 1999; 160(6):1862-1868.
18. Lofdahl CG, Reiss TF, Leff JA, Israel E, Noonan MJ, Finn AF, Seidenberg BC, Capizzi T, Kundu S, Godard P. Randomised, Placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. BMJ 1999; 319(7202):87-90.
19. Turner-Warwick M. Epidemiology of nocturnal asthma. Am J Med 1988; 85(1B):6-8.
20. Walters EH, Bjermer L, Faurschou P, Sandstrom T. The anti-inflammatory profile of inhaled corticosteroids combined with salmeterol in asthmatic patients. Respir Med 2000; 94(suppl F):S26-S31.
21. Donohue JF, Ohar JA. New combination therapies for asthma. Curr Opin Pulm Med 2001; 7(2):62-68.
22. Holimon TD, Chafin CC, Self TH. Nocturnal asthma uncontrolled by inhaled corticosteroids: theophylline or long-acting beta2 agonists? Drugs 2001; 61(3):391-418.
23. Wallaert B, Brun P, Ostinelli J, Murciano D, Champel F, Blaive B, Montane F, Godard P. A comparison of two long-acting beta-agonists, oral bambuterol and inhaled salmeterol, in the treatment of moderate to severe asthmatic patients with nocturnal symptoms. The French bambuterol study group. Respir Med 1999; 93(1):33-38.
24. Wiegand L, Mende CN, Zaidel G, Zwillich CW, Petrocella VJ, Yancey SW, Rickard KA. Salmeterol vs. theophylline: sleep and efficacy outcomes in patients with nocturnal asthma. Chest 1999; 115(6):1525-1532.
25. Lockey RF, DuBuske LM, Friedman B, Petrocella V, Cox F, Rickard K. Nocturnal asthma: effect of salmeterol on quality of life and clinical outcomes. Chest 1999; 115(3):666-673.
26. Woolcock A, Lundback B, Ringdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996; 153(5):1481-1488.
27. Busse W, Nelson H, Wolfe J, Kalberg C, Yancey SW, Rickard KA. Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma. J Allergy Clin Immunol 1999; 103(6):1075-1080.
28. Edelman JM, Turpin JA, Bronsky EA, Grossman J, Kemp JP, Ghannam AF, DeLucca PT, Gormley GJ, Pearlman DS. Oral montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction. A randomized, double-blind trial. Exercise study group. Ann Intern Med 2000; 132(2):97-104.
29. Volovitz B, Tabachnik E, Nussinovitch M, Shtaif B, Blau H, Gil-Ad I, Weizman A, Varsano I. Montelukast, a leukotriene receptor antagonist, reduces the concentration of leukotrienes in the respiratory tract of children with persistent asthma. J Allergy Clin Immunol 1999; 104(6):1162-1167.
30. Bratton DL, Lanz MJ, Miyazawa N, White CW, Silkoff PE. Exhaled nitric oxide before and after montelukast sodium therapy in school-age children with chronic asthma: a preliminary study. Pediatr Pulmonol 1999; 28(6):402-407.
31. Bisgaard H, Loland L, Oj JA. NO in exhaled air of asthmatic children is reduced by the leukotriene receptor antagonist montelukast. Am J Respir Crit Care Med 1999; 160(4):1227-1231.
32. Roberts JA, Bradding P, Britten KM, Walls AF, Wilson S, Gratziou C, Holgate ST, Howarth PH. The long-acting beta2-agonist salmeterol xinafoate: effects on airway inflammation in asthma. Eur Respir J 1999; 14(2):275-282.
33. Calhoun WJ, Hinton KL, Kratzenberg JJ. The effect of salmeterol on markers of airway inflammation following segmental allergen challenge. Am J Respir Crit Care Med 2001, 163(4):881-886.
34. McIvor RA, Pizzichini E, Turner MO, HussackP, Hargreave FE, Sears MR. Potential masking effects of salmeterol on airway inflammation in asthma. Am J Respir Crit Care Med 1998; 158(3):924-930.
35. Bjermer L, Bisgaard H, Bousquet J, Fabbri LM, Greening A, Haahtela T, Holgate ST, Picado C, Leff JA. Montelukast or salmeterol combined with an inhaled steroid in adult asthma: design and rationale of a randomized, double-blind comparative study (the IMPACT investigation of montelukast as a partner agent for complementary therapy trial). Respir Med 2000; 94(6):612-621.
36. Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids. Eur Respir J 2002; 19(1):182-191.
37. Chung KF. The complementary role of glucocorticosteroids and long-acting beta-adrenergic agonists. Allergy 1998; 53(suppl):7-13.
38. Collins S, Caron MG, Lefkowitz RJ. Beta-adrenergic receptors in hamster smooth muscle cells are transcriptionally regulated by glucocorticoids. J Biol Chem 1988; 263(19):9067-9070.
39. Hadcock JR, Malbon CC. Regulation of beta-adrenergic receptors by "permissive" hormones: glucocorticoids increase steady-state levels of receptor mRNA. Proc Natl Acad Sci USA 1988; 85(22):8415-8419.
40. Eickelberg O, Roth M, Lorx R, Bruce V, Rudiger J, Johnson M, Block LH. Ligand-independent activation of the glucocorticoid receptor by beta2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J Biol Chem 1999; 274(2):1005-1010.
41. Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ 2000; 320(7246):1368-1373.
42. Hoshino M, Nakamura Y, Sim JJ, Yamashiro Y, Uchida K, Hosaka K, Isogai S. Inhaled corticosteroid reduced lamina reticularis of the basement membrane by modulation of insulin-like growth factor (IGF)-I expression in bronchial asthma. Clin Exp Allergy 1998; 28(5):568-577.
43. Newnham DM, Grove A, McDevitt DG, Lipworth BJ. Subsensitivity of bronchodilator and systemic beta 2 adrenoceptor responses after regular twice daily treatment with eformoterol dry powder in asthmatic patients. Thorax 1995; 50(5):497-504.
44. Nelson HS, Raine D Jr, Doner HC, Posey WC. Subsensitivity to the bronchodilator action of albuterol produced by chronic administration. Am Rev Respir Dis 1977; 116(5):871-878.
45. Galant SP, Duriseti L, Underwood S, Insel PA. Decreased beta-adrenergic receptors on polymorphonuclear leukocytes after adrenergic therapy. N Engl J Med 1978; 299(17):933-936.
46. Grove A, Lipworth BJ. Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients. Lancet 1995; 346(8969):201-206.
47. Fuglsang G, Vikre-Jorgensen J, Agertoft L, Pedersen S. Effect of salmeterol treatment on nitric oxide level in exhaled air and doseresponse to terbutaline in children with mild asthma. Pediatr Pulmonol 1998; 25(5):314-321.
48. Booth H, Bish R, Walters J, Whitehead F, Walters EH. Salmeterol tachyphylaxis in steroid treated asthmatic subjects. Thorax 1996; 51(11):1100-1104.
49. Villaran C, O'Neill SJ, Helbling A, van Noord JA, Lee TH, Chuchalin AG, Langley SJ, Gunawardena KA, Suskovic S, Laurenzi M, Jasan J, Menten J, Leff JA. Montelukast versus salmeterol in patients with asthma and exercise-induced bronchoconstriction. Montelukast/salmeterol exercise study group. J Allergy Clin Immunol 1999; 104(3 Pt 1):547-553.
50. Tan KS, Grove A, McLean A, Gnosspelius Y, Hall IP, Lipworth BJ. Systemic corticosteriod rapidly reverses bronchodilator subsensitivity induced by formoterol in asthmatic patients. Am J Respir Crit Care Med 1997; 156(1):28-35.
51. Aziz I, Lipworth BJ. A bolus of inhaled budesonide rapidly reverses airway subsensitivity and beta2-adrenoceptor down-regulation after regular inhaled formoterol. Chest 1999; 115(3):623-628.
52. Kalra S, Swystun VA, Bhagat R, Cockcroft DW. Inhaled corticosteroids do not prevent the development of tolerance to the broncho-protective effect of salmeterol. Chest 1996; 109(4):953-956.
53. Yates DH, Kharitonov SA, Barnes PJ. An inhaled glucocorticoid does not prevent tolerance to the bronchoprotective effect of a long-acting inhaled beta 2-agonist. Am J Respir Crit Care Med 1996; 154(6 Pt 1):1603-1607.
54. Jack CI, Lye M. Asthma in the elderly patient. Gerontology 1996; 42(2):61-68.
55. Schocken DD, Roth GS. Reduced beta-adrenergic receptor concentrations in ageing man. Nature 1977; 267(5614):856-858.
56. Palmqvist M, Arvidsson P, Beckman O, Peterson S, Lotvall J. Onset of bronchodilation of budesonide/formoterol vs. salmeterol/fluticasone in single inhalers. Pulm Pharmacol Ther 2001; 14(1):29-34.
57. Fink JB. Metered-dose inhalers, dry powder inhalers, and transitions. Respir Care 2000; 45(6):623-635.
58. Van den Berg NJ, Ossip MS, Hederos CA, Anttila H, Ribeiro BL, Davies PI. Salmeterol/fluticasone propionate (50/100μg) in combination in a diskus inhaler (seretide) is effective and safe in children with asthma. Pediatr Pulmonol 2000; 30(2):97-105.
59. Sheth KK, Kelly HW, Mitchell BH. Innovations in Dry Powder Inhalers [monograph]. Bala Cynwyd, PA: Meniscus, 2000.
60. Bateman ED, Silins V, Bogolubov M. Clinical equivalence of salmeterol/fluticasone propionate in combination (50/100 μg twice daily) when administered via a chlorofluorocarbon-free metered dose inhaler or dry powder inhaler to patients with mild-to-moderate asthma. Respir Med 2001; 95(2):136-146.
61. Condemi JJ, Goldstein S, Kalberg C, Yancey S, Emmett A, Rickard K. The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma. Salmeterol study group. Ann Allergy Asthma Immunol 1999; 82(4):383-389.
62. van Noord JA, Schreurs AJ, Mol SJ, Mulder PG. Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma. Thorax 1999; 54(3):207-212.
63. Spencer CM, Jarvis B. Salmeterol/fluticasone propionate combination. Drugs 1999; 57(6):933-940.
64. D'Alonzo GE, Crocetti JG, Smolensky MH. Circadian rhythms in the pharmacokinetics and clinical effects of beta-agonist, theophylline, and anticholinergic medications in the treatment of nocturnal asthma. Chronobiol Int 1999; 16(5):663-682.
65. Faurschou P, Engel AM, Haanaes OC. Salmeterol in two different doses in the treatment of nocturnal bronchial asthma poorly controlled by other therapies. Allergy 1994; 49(10):827-832.
66. Pincus DJ, Humeston TR, Martin RJ. Further studies on the chronotherapy of asthma with inhaled steroids: the effect of dosage timing on drug efficacy. J Allergy Clin Immunol 1997; 100(6 Pt 1):771-774.
67. Kavuru M, Melamed J, Gross G, LaForce C, House K, Prillaman B, Baitinger L, Woodring A, Shah T. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2000; 105(6 Pt 1):1108-1116.
68. Shapiro G, Lumry W, Wolfe J, Given J, White MV, Woodring A, Baitinger L, House K, Prillaman B, Shah T. Combined salmeterol 50 μg and fluticasone propionate 250 μg in the diskus device for the treatment of asthma. Am J Respir Crit Care Med 2000; 161(2 Pt 1):527-534.
69. Aubier M, Pieters WR, Schlosser NJ, Steinmetz KO. Salmeterol/fluticasone propionate (50/500 μg) in combination in a diskus inhaler (seretide) is effective and safe in the treatment of steroid-dependent asthma. Respir Med 1999; 93(12):876-884.
70. Bateman ED, Britton M, Carrillo AJ, Wixon X. Salmeterol/fluticasone combination inhaler. A new, effective and well tolerated treatment for asthma. Clin Drug Invest 1998; 16:193-201.
71. Chapman KR, Ringdal N, Backer V, Palmqvist M, Saarelainen S, Briggs M. Salmeterol and fluticasone propionate (50/250 μg) administered via combination diskus inhaler: as effective as when given via separate diskus inhalers. Can Respir J 1999; 6(1):45-51.
72. Markham A, Jarvis B. Inhaled salmeterol/fluticasone propionate combination: a review of its use in persistent asthma. Drugs 2000; 60(5):1207-1233.
73. Centanni S, Carlucci P, Santus P, Boveri B, Tarricone D, Fiorentini C, Lombardi F, Cazzola M. Non-pulmonary effects induced by the addition of formoterol to budesonide therapy in patients with mild or moderate persistent asthma. Respiration 2000; 67(1):60-64.
74. Nelson HS, Busse WW, Kerwin E, Church N, Emmett A, Rickard K, Knobil K. Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. J Allergy Clin Immunol 2000; 106(6): 1088-1095.
75. Jenkins C, Woolcock AJ, Saarelainen P, Lundback B, James MH. Salmeterol/fluticasone propionate combination therapy 50/250 μg twice daily is more effective than budesonide 800 μg twice daily in treating moderate to severe asthma. Respir Med 2000; 94(7):715-723.
76. Kraft M. The distal airways: are they important in asthma? Eur Respir J 1999; 14(6):1403-1417.
77. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet 1994; 344(8917):219-224.
78. Pauwels RA, Lofdahl CG, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, Ullman A. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and corticosteroids establishing therapy (FACET) international study group. N Engl J Med 1997; 337(20):1405-1411.